2-chloro-N-(4-nitrobenzyl)acetamide | 38426-11-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-N-(4-nitrobenzyl)acetamide
• 英文别名: 2-chloro-N-[(4-nitrophenyl)methyl]acetamide
• CAS: 38426-11-8
• 化学式: C₉H₉ClN₂O₃
• mdl: MFCD12761922
• 分子量: 228.635
• InChiKey: VFBUDPDUPLYXIC-UHFFFAOYSA-N

物化性质

• 熔点：
  113-114 °C
• 沸点：
  474.6±35.0 °C(Predicted)
• 密度：
  1.361±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2-chloro-N-(4-nitrobenzyl)acetamide 在 吡啶 、 铁粉 、 氯化铵 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 乙醇 、 水 、 正丁醇 为溶剂， 反应 11.0h， 生成 4-(dimethylamino)-N-[4-({2-[(4-oxo-4H-chromen-7-yl)oxy]acetamido}methyl)phenyl]benzamide
  参考文献：
  名称：

  Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models

  摘要：

  Diabetic retinopathy (DR) is a major cause of blindness, and there is a lack of effective treatment at present. Rho-associated coiled-coil containing serine/threonine protein kinases (ROCKs) have recently been suggested as potential targets for the DR treatment. We herein report the discovery of 4H-chromen-4-one derivatives as a new class of ROCK inhibitors. Structure-activity relationship analyses led to the identification of the most active compound, 4-(dimethylamino)-N-(3-{2-[(4-oxo-4H-chromen-7-yl)oxy]acetamido}phenyl) (12j). This compound showed excellent kinase selectivity for ROCK I and ROCK II against 387 other kinases. In retinal explants, compound 12j protected retinal neurons from high glucose-induced oxidative stress and apoptosis-mediated cell death. Furthermore, 12j administration suppressed the improper proliferation of Muller cells and promoted the regression of vascular vessels in retinal explants cultured in a high glucose microenvironment. Collectively, our data suggest that 12j could be a potential lead compound for the treatment of DR, hence deserving further in-depth studies.

  DOI：

  10.1021/acs.jmedchem.9b01143
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 、 硝酸 作用下， 生成 2-chloro-N-(4-nitrobenzyl)acetamide
  参考文献：
  名称：

  Isshiki; Kuwada, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1952, vol. 72, p. 69,71

  摘要：

  DOI：

文献信息

• Tricycloundecane compounds useful as modulators of nuclear hormone receptor function
  申请人：Balog Aaron James

  公开号：US20070088029A1

  公开（公告）日：2007-04-19

  Tricycloundecanes compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds are disclosed.

  三环十一烷化合物，以及在治疗核激素受体相关疾病如癌症和免疫紊乱中使用这些化合物的方法，以及含有这些化合物的药物组合物被披露。
• Lead Optimization and Structure–Activity Relationship Studies on Myeloid Ecotropic Viral Integration Site 1 Inhibitor
  作者：Bengisu Turgutalp、Merve Uslu、Sinem Helvacioglu、Mohammad Charehsaz、Enise Ece Gurdal、Wolfgang Sippl、Fatih Kocabas、Mine Yarim

  DOI：10.1021/acs.jmedchem.1c00972

  日期：2021.10.14

  site (MEIS) inhibitor, MEISi-1, to induce murine and human HSC expansion ex vivo and in vivo. In this work, we performed lead optimization on MEISi-1 by synthesizing 45 novel analogues. Structure–activity relationship studies revealed the significance of a para-methoxy group on ring A and a hydrophobic moiety at the meta position of ring B. Obtained biological data were supported by inhibitor docking and

  我们之前的研究结果报道了骨髓嗜嗜性病毒整合位点 1 (MEIS1) 转录因子在心脏再生和造血干细胞 (HSC) 调节中的关键作用。MEIS1 作为药理抑制背景下的一个有希望的靶点，我们鉴定了一种有效的髓系亲嗜性病毒整合位点 (MEIS) 抑制剂 MEISi-1，可在体外和体内诱导小鼠和人类 HSC 扩增。在这项工作中，我们通过合成 45 种新型类似物对 MEISi-1 进行了先导优化。构效关系研究揭示了环A上的对甲氧基和环B间位的疏水部分的重要性. 获得的生物学数据得到了抑制剂对接和分子动力学模拟研究的支持。11 种化合物被描述为强效抑制剂，证明对 MEIS1 和靶基因Meis1、Hif-1 α 和p21具有更好的抑制作用。其中，4h、4f和4b是最有效的抑制剂。预测的药代动力学特性满足药物相似性标准。此外，化合物对人皮肤成纤维细胞既没有细胞毒性，也没有致突变性。
• Chemodivergent Staudinger Reactions of Secondary Phosphine Oxides and Application to the Total Synthesis of LL–D05139β Potassium Salt
  作者：Wenjun Luo、Fang Xu、Zhenguo Wang、Jiyan Pang、Zixu Wang、Zhixiu Sun、Aiyun Peng、Xiaohui Cao、Le Li

  DOI：10.1002/anie.202310118

  日期：2023.10.9

  Unprecedented chemodivergent Staudinger reactions of secondary phosphine oxides (SPO) have been developed. Reagent-controlled 1- or 2-nitrogen atom exclusions from azides have been achieved. Conversion of a chiral SPO to a phosphinic amide was stereoretentive, and the potassium salt of natural product LL-D05139β was synthesized for the first time.

  二级氧化膦 (SPO) 史无前例的化学发散施陶丁格反应已经开发出来。已经实现了试剂控制的 1-或 2-氮原子从叠氮化物中的排除。手性SPO立体保留转化为次膦酰胺，首次合成了天然产物LL-D05139β的钾盐。
• Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening
  作者：Mingming Zhang、Weiliang Zhu、Yingxia Li

  DOI：10.1016/j.ejmech.2013.01.009

  日期：2013.4

  Inhibition of the signal transducer and activator of transcription 3 (STAT3) signaling pathway has been considered a novel therapeutic strategy to treat human cancers that harbor aberrantly-active STAT3. In this study, nearly 204,000 compounds in Specs database were screened by virtual screening, and samples of top 100 compounds identified as candidate small-molecule inhibitors of STAT3 were evaluated by STAT3-dependent luciferase reporter assay as well as other cell-based assays. A benzothiazole core scaffold containing compound, 9, was identified as an inhibitor of IL-6/STAT3 signaling with an IC50 of 3.567 mu M. It is the first time to discover benzothiazole scaffold as a potent STAT3 signaling inhibitor. We further investigated the (structure activity relationship) SAR of the benzothiazole analogues, and discovered compound 16w as a better small-molecule inhibitor. Both compounds inhibited the phosphorylation of STAT3 and had no obvious effect on upstream JAK2 kinase. (C) 2013 Elsevier Masson SAS. All rights reserved.
• Discovery and structure-activity relationships study of thieno[2,3-b]pyridine analogues as hepatic gluconeogenesis inhibitors
  作者：Fei Ma、Jian Liu、Tingting Zhou、Min Lei、Jing Chen、Xiachang Wang、Yinan Zhang、Xu Shen、Lihong Hu

  DOI：10.1016/j.ejmech.2018.04.028

  日期：2018.5

  Type 2 diabetes mellitus (T2DM) is a chronic, complex and multifactorial metabolic disorder, and targeting gluconeogenesis inhibition is a promising strategy for anti-diabetic drug discovery. This study discovered a new class of thieno[2,3-b]pyridine derivatives as hepatic gluconeogenesis inhibitors. First, a hit compound (DMT: IC50 = 33.8 mu M) characterized by a thienopyridine core was identified in a cell based screening of our privileged small molecule library. Structure activity relationships (SARs) study showed that replaced the CF3 in the thienopyridine core could improve the potency and led to the discovery of 8e (IC50 = 16.8 mu M) and 9d (IC50 = 12.3 mu M) with potent inhibition of hepatic glucose production and good drug-like properties. Furthermore, the mechanism of 8e for the inhibition of hepatic glucose production was also identified, which could be effective through the reductive expression of the mRNA transcription level of gluconeogenic genes, including glucose-6-phosphatase (G6Pase) and hepatic phosphoenolpyruvate carboxykinase (PEPCK). Additionally, 8e could also reduce the fasting blood glucose and improve the oral glucose tolerance and pyruvate tolerance in db/db mice. The optimization of this class of derivatives had provided us a start point to develop new anti-hepatic gluconeogenesis agents. (C) 2018 Elsevier Masson SAS. All rights reserved.